AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02214407
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
Trial: NCT02214407
Drug: HYDROXYUREA
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
Trial: NCT00097435
Drug: Albuferon
RxNorm normalized name: Albuferon alpha
DrugBank: Albinterferon Alfa-2B (DB05396)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00097435
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00887653
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
Trial: NCT00739232
Drug: HSD-016
RxNorm normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02439190
Drug: BMS-986120
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02439190
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02439190
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm1
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
Trial: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm2
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
Trial: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm3
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator.
Trial: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm4
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
Trial: NCT01578174
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Trial: NCT03693300
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
Trial: NCT03198650
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib
Trial: NCT03198650
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab
Trial: NCT00000563
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01244659
Drug: Tacrolimus from EMS
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Trial: NCT01244659
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Trial: NCT02524379
Drug: Glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
Trial: NCT01951950
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01951950
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03996603
Drug: Conjugated Estrogens Cream
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
Trial: NCT00003584
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003584
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003584
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00783406
Drug: PF-00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder inhaler, 1472 mcg, single dose
Trial: NCT00783406
Drug: PF-00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder inhaler, 736 mcg, single dose
Trial: NCT00783406
Drug: PF-00610355
RxNorm normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder inhaler, 368 mcg, single dose
Trial: NCT01367275
Drug: Brivanib
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
Trial: NCT01367275
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
Trial: NCT00750659
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
Trial: NCT02237183
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via inhalation
Trial: NCT01947777
Drug: IPI-145
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg oral capsule
Trial: NCT01947777
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x 300 mg oral capsule
Trial: NCT00409994
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
Trial: NCT00941928
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
Trial: NCT00941928
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
Trial: NCT00941928
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
Trial: NCT01855724
Drug: Gemcitabine-Pazopanib
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00941928
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
Trial: NCT02300610
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
Trial: NCT02300610
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
Trial: NCT02300610
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
Trial: NCT00577408
Drug: depot naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
Trial: NCT00577408
Drug: Oral Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
Trial: NCT00141921
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
Trial: NCT00968162
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
Trial: NCT00150709
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use
Trial: NCT02221830
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
Trial: NCT00090038
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose, schedule,and duration specified in protocol
Trial: NCT00382304
Drug: tolevamer potassium-sodium (GT267-004)
RxNorm normalized name: Potassium Sodium Tartrate
DrugBank: Tolevamer (DB01344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03913000
Drug: ID-085
RxNorm normalized name: menthol 0.085 MG/MG
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsules for oral administration formulated at a strength of 200 mg
Trial: NCT01577368
Drug: Piperacillin-Tazobactam continuous infusion
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
Trial: NCT01577368
Drug: Piperacillin-Tazobactam intermittent infusion
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
Trial: NCT03555032
Drug: Talimogene laherparepvec (T-VEC)
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
Trial: NCT03377400
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: concurrent radiotherapy
Trial: NCT00502775
Drug: fluticasone furoate, fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00998699
Drug: Xoma 052
RxNorm normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Trial: NCT02586259
Drug: budesonide MMX®
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02336737
Drug: Isosulfan blue dye
RxNorm normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of a single dose of isosulfan blue dye
Trial: NCT02899130
Drug: Polyherbal
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
Trial: NCT00344552
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
Trial: NCT00356200
Drug: Fluphenazine Decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym.
Trial: NCT00635778
Drug: dalotuzumab
RxNorm normalized name: DALOTUZUMAB
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion over one to two hours
Trial: NCT02349061
Drug: Ustekinumab IV
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
Trial: NCT02349061
Drug: Ustekinumab SC
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
Trial: NCT01397162
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate
Trial: NCT01397162
Drug: BI 54903
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 54903
Trial: NCT01560403
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05 mg/kg/day subcutaneously taken once per day for 12 months
Trial: NCT00812253
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Trial: NCT03882047
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray, 200 mg once daily
Trial: NCT00385762
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paroxetine 10-40mg daily x 5 weeks
Trial: NCT01842321
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
Trial: NCT01164800
Drug: Trandolapril
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
Trial: NCT01164800
Drug: Mavik
RxNorm normalized name: Mavik
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mavik® 4 mg Tablets of Abbott Laboratories, USA.
Trial: NCT00541684
Drug: Comparator : atenolol /Duration of Treatment : 16 Weeks
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01805375
Drug: DI-B4
RxNorm normalized name: di-isopropylammonium
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
Trial: NCT03994107
Drug: Albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
Trial: NCT03994107
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
Trial: NCT03882047
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray, 200 mg once daily
Trial: NCT04009616
Drug: Aloe Vera mouthwash
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rinsing with aloe vera mouthwash for 5 days.
Trial: NCT04009616
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rinsing with chlorhexidine mouthwash for 5 days.
Trial: NCT03882047
Drug: Mometasone furoate placebo
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate placebo matching nasal spray, once daily
Trial: NCT03065062
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.